查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1676748

環肽市場：按類型、產品、技術、應用和最終用戶 - 2025-2030 年全球預測

Cyclic Peptides Market by Type, Product, Technology, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

環肽市場規模在 2024 年預計為 1116.2 億美元，預計在 2025 年將成長至 1186.2 億美元，複合年成長率為 6.51%，預計到 2030 年將達到 1629.8 億美元。

主要市場統計數據
基準年 2024 年 1116.2億美元
預計 2025 年 1186.2億美元
預測年份 2030 1629.8億美元
複合年成長率（%） 6.51%

環肽已成為一類動態和變革性生物分子，正在重塑現代生物醫學的典範。其獨特的結構特性——增強穩定性並賦予抗酶分解性的環狀骨架——使其能夠有效地發揮線性肽通常缺乏的功能。隨著研究人員和行業專業人士對胜肽化學的深入探索，環肽在從藥物設計到診斷創新等各種應用領域的潛力越來越受到認可。

在過去的十年中，對研發的大量投資推動了合成方法和技術平台的快速發展。這項進步為提高胜肽合成的擴充性和精確度鋪平了道路，最終有助於改善治療效果。環肽將自然啟發的分子框架與複雜的化學合成相結合，不僅擴展了傳統藥理學的邊界，而且還在腫瘤學、代謝和感染疾病等領域開闢了新的治療機會。

該領域的不斷發展也反映了有機化學、分子生物學和臨床研究之間更深層的跨學科合作。隨著該領域的成熟，技術創新、市場動態和監管環境的相互作用有望重新定義全球治療策略。在以下章節中，我們將深入探討不斷變化的行業格局、關鍵細分見解以及引導當今行業領導者的各個地區和公司的影響力。

改變環肽市場

環狀胜肽市場正在經歷推動創新和成長的變革。市場發展趨勢表明，尖端合成技術擴大與尖端篩檢方法相結合，以實現快速的發現週期並加速產品開發。溶液和固相合成的改進等先驅技術進步正在重新定義胜肽的生產方式，使其滿足特定的臨床需求。

除了技術創新之外，受個人化醫療和標靶治療解決方案日益成長的需求的影響，該領域還經歷著重大的監管變革。這些因素正在加速從傳統鎖狀肽模型轉向具有卓越功效和安全性的環狀結構的轉變。

此外，學術研究中心、生技公司和製藥公司之間的合作日益增多，形成了共用專業知識和風險的環境。隨著此類合作變得越來越普遍，跨學科研究和商業性洞察的融合可能會進一步突破界限。最終，這些轉變不僅將重塑競爭格局，而且還將為滿足不斷變化的患者需求和行業條件的新型、具有成本效益、有影響力的醫療保健解決方案鋪平道路。

循環胜肽市場的關鍵細分見解

為了了解環狀胜肽市場的複雜動態，深入研究細分可以從幾個方面提供關鍵見解。分析首先從基於類型的細分開始，將市場分為天然環肽和合成環肽。這種差異突顯了創新的雙重來源：天然胜肽具有固有的生物相容性，而合成胜肽則提供了結構修飾的機會以增強治療效果。

依產品類型進一步分類可發現多樣化的產品組合，包括抗菌胜肽、荷爾蒙胜肽、免疫調節胜肽和胜肽疫苗。其中，荷爾蒙胜肽的研究越來越深入，特別是從其在胰島素類似物和肽激素治療中的應用角度。這種詳細的審查將有助於針對可以進一步最佳化肽療法的特定治療領域。

分割的技術方面包括化學合成、雜交技術、溶液相合成、重組 DNA 技術和固相合成。每種方法都透過影響產品品質、擴充性和成本效益來做出獨特的貢獻。從應用方面來看，市場分為診斷、環境保護、研發和治療。在這些大類中，診斷學進一步分為生物感測器和免疫測量，研究和開發分為生化分析、藥物發現和分子生物學，治療學則涵蓋心血管護理、感染疾病干預、代謝紊亂管理和腫瘤學等廣泛領域。

最後，基於最終用戶的細分突顯了學術機構、生技公司和製藥公司所扮演的角色。這種多層次的細分方法不僅強調了決定市場趨勢的多種因素的相互作用，而且還強調了每個細分市場的目標策略對於永續成長和創新的重要性。

目錄

第 1 章 簡介

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 慢性病和癌症發生率不斷上升，推動創新環狀胜肽的需求
      • 以肽療法為重點的生物製藥行業的擴張正在推動對環肽的需求
      • 政府對藥物開發的獎勵和津貼鼓勵探索環肽療法
    • 限制因素
      • 與胜肽穩定性和生物利用度相關的問題
    • 機會
      • 環肽在環境永續農藥設計上的創新應用
      • 創新環肽修飾以改善治療藥物開發的藥物動力學
    • 任務
      • 環肽生產的複雜性
  • 市場區隔分析
    • 類型：天然環肽因具有有效調節生物途徑的能力而需求量很大。
    • 應用：高特異性和穩定性使得環肽在診斷上的應用越來越廣泛。
  • 波特五力分析
  • PESTEL 分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

第6章 環肽市場按類型

  • 天然環肽
  • 合成環肽

第7章 環肽市場（按產品）

  • 抗菌胜肽
  • 荷爾蒙胜肽
    • 胰島素類似物
    • 肽激素治療
  • 免疫調節胜肽
  • 胜肽疫苗

第 8 章 環肽市場（按技術）

  • 化學合成
  • 混合技術
  • 液相合成
  • 重組DNA技術
  • 固相合成

第9章 環肽市場按應用

  • 診斷
    • 生物感測器
    • 免疫檢測
  • 環境保護
  • 研究與開發
    • 生化分析
    • 藥物研發
    • 分子生物學
  • 治療
    • 心血管
    • 感染疾病
    • 代謝紊亂
    • 腫瘤學

第 10 章 環肽市場（依最終用戶）

  • 學術機構
  • 生技公司
  • 製藥公司

11. 美洲循環胜肽市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

12. 亞太地區循環胜肽市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

13. 歐洲、中東和非洲環肽市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章 競爭格局

  • 2024 年市場佔有率分析
  • FPNV 定位矩陣，2024 年
  • 競爭情境分析
  • 戰略分析與建議

公司列表

  • Amgen Inc.
  • AnaSpec
  • Astellas Inc.
  • Asymchem Inc.
  • Bachem Holding AG
  • Bristol-Myers Squibb Company
  • Clariant International Ltd
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Insamo
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pepscan Therapeutics BV
  • PeptiDream Inc.
  • Pfizer Inc.
  • Sanofi SA
  • SciTide LLC
  • Zealand Pharma AS
Product Code: MRR-AE420CB152AD

The Cyclic Peptides Market was valued at USD 111.62 billion in 2024 and is projected to grow to USD 118.62 billion in 2025, with a CAGR of 6.51%, reaching USD 162.98 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 111.62 billion
Estimated Year [2025] USD 118.62 billion
Forecast Year [2030] USD 162.98 billion
CAGR (%) 6.51%

Cyclic peptides have emerged as a dynamic and transformative class of biomolecules that are reshaping the paradigms of modern biomedical science. Their unique structural characteristics-circular backbones that impart enhanced stability and resistance to enzymatic degradation-allow them to function effectively where linear peptides often fall short. As researchers and industry experts explore the depths of peptide chemistry, cyclic peptides are increasingly recognized for their potential in diverse applications ranging from drug design to diagnostic innovations.

Over the past decade, substantial investments in research and development have catalyzed breakthroughs in synthetic methodologies and technology platforms. This progress has paved the way for enhanced scalability and precision in peptide synthesis, ultimately contributing to improved therapeutic outcomes. In blending nature-inspired molecular frameworks with sophisticated chemical synthesis, cyclic peptides are not only expanding the boundaries of traditional pharmacology but are also presenting new therapeutic opportunities in oncological, metabolic, and infectious disease contexts.

The ongoing evolution in this field is also a reflection of deeper cross-disciplinary collaboration spanning organic chemistry, molecular biology, and clinical research. As this sector matures, the interplay between innovation, market dynamics, and regulatory landscapes promises to redefine therapeutic strategies worldwide. The following sections delve into transformative shifts in the landscape, key segmentation insights, and a range of regional and corporate influences that are guiding industry leaders today.

Transformative Shifts in the Cyclic Peptides Landscape

The cyclic peptides market has witnessed transformative shifts that are driving both innovation and growth. Market trends now reveal an increasing convergence of advanced synthesis techniques with state-of-the-art screening methods, leading to rapid discovery cycles and accelerated product development. Pioneering technological advancements, such as improvements in liquid-phase and solid-phase synthesis, are redefining how peptides are produced and tailored for specific clinical needs.

Beyond technological innovations, the sector has experienced significant regulatory evolution, further influenced by growing demand for personalized medicine and targeted therapeutic solutions. These factors have expedited the transition from traditional linear peptide models to cyclic structures that offer superior efficacy and safety profiles.

Moreover, increasing collaborations between academic research centers, biotechnology firms, and pharmaceutical companies are fostering an environment of shared expertise and risk. As these partnerships become more prevalent, the integration of interdisciplinary research and commercial insights is set to push the envelope even further. Ultimately, these shifts have not only restructured competitive landscapes but are also opening up new avenues for cost-effective, high-impact healthcare solutions that cater to evolving patient needs and industry demands.

Key Segmentation Insights for the Cyclic Peptides Market

In understanding the complex dynamics of the cyclic peptides market, a deep dive into segmentation provides critical insights on several fronts. The analysis begins with the type-based segmentation, where the market is bifurcated into natural cyclic peptides and synthetic cyclic peptides. This distinction highlights the dual sources of innovation, with natural peptides offering inherent biological compatibility and synthetic variants providing opportunities for structural modifications to enhance therapeutic efficacy.

Further segmentation based on product reveals a diverse portfolio that includes antimicrobial peptides, hormonal peptides, immunomodulating peptides, and peptide vaccines. Among these, hormonal peptides are studied in greater depth, particularly in terms of their applications in insulin analogs and peptide hormone therapy. Such detailed scrutiny helps in targeting specific therapeutic areas where peptide treatments can be further optimized.

The technological dimension of segmentation encompasses chemical synthesis, hybrid technology, liquid-phase synthesis, recombinant DNA technology, and solid-phase synthesis. Each methodology contributes uniquely by influencing product quality, scalability, and cost efficiency. In the realm of application, the market is segmented into diagnostics, environmental protection, research and development, and therapeutics. Within these broad categories, diagnostics is further dissected into biosensors and immunoassays, research and development into biochemical analysis, drug discovery, and molecular biology, while therapeutics covers a gamut that includes cardiovascular treatments, interventions for infectious diseases, metabolic disorder management, and oncology.

Finally, the segmentation based on end users sheds light on the roles played by academic institutes, biotechnology firms, and pharmaceutical companies. This layered segmentation approach not only underscores the interplay of multiple factors in determining market trends but also reinforces the importance of targeted strategies in each segment for sustainable growth and innovation.

Based on Type, market is studied across Natural Cyclic Peptide and Synthetic Cyclic Peptide.

Based on Product, market is studied across Antimicrobial Peptides, Hormonal Peptides, Immunomodulating Peptides, and Peptide Vaccines. The Hormonal Peptides is further studied across Insulin Analogs and Peptide Hormone Therapy.

Based on Technology, market is studied across Chemical Synthesis, Hybrid Technology, Liquid-Phase Synthesis, Recombinant DNA Technology, and Solid-Phase Synthesis.

Based on Application, market is studied across Diagnostics, Environmental Protection, Research & Development, and Therapeutics. The Diagnostics is further studied across Biosensors and Immunoassays. The Research & Development is further studied across Biochemical Analysis, Drug Discovery, and Molecular Biology. The Therapeutics is further studied across Cardiovascular, Infectious Diseases, Metabolic Disorders, and Oncology.

Based on End User, market is studied across Academic Institutes, Biotechnology Firms, and Pharmaceutical Companies.

Key Regional Insights Shaping the Global Market

Examining the cyclic peptides market through a regional lens reveals nuanced variations in demand, adoption, and innovation. In the Americas, robust healthcare infrastructures and a strong emphasis on biomolecular research have paved the way for dynamic market growth. This region has been at the forefront of integrating advanced synthetic methods with clinical applications, reflecting the high level of both public and private investment in biomedical research.

Turning to the Europe, Middle East & Africa region, a combination of stringent regulatory frameworks, strong academic foundations, and growing collaborative networks is rapidly transforming the landscape. Here, the focus is driven by a balance between innovation and compliance, ensuring that advancements in cyclic peptides are both cutting-edge and safe.

The Asia-Pacific region, on the other hand, is experiencing rapid expansion thanks to increasing R&D investments, progressive government initiatives, and a burgeoning pharmaceutical sector. With a blend of traditional medicinal practices and modern synthetic techniques, this region is emerging as a pivotal player in the global cyclic peptides market. Overall, the regional insights underscore a diverse yet interconnected market, where localized strategies and global trends converge to shape the future of cyclic peptides.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Company Insights in the Cyclic Peptides Sector

Leading companies in the cyclic peptides market exemplify the drive toward innovation and excellence that characterizes the industry. Industry pioneers such as Amgen Inc. and Bristol-Myers Squibb Company have invested significantly in both natural and synthetic peptide research, setting high benchmarks in therapeutic and diagnostic development. Key players including AnaSpec, Astellas Inc., and Asymchem Inc. contribute to the diversification of product portfolios by developing novel synthesis technologies and advanced drug delivery systems.

Additionally, companies like Bachem Holding AG, Clariant International Ltd, and F. Hoffmann-La Roche AG are renowned for their robust research programs that focus on optimizing peptide stability and efficacy, further cementing their roles as industry leaders. Not to be overlooked, pharmaceutical giants such as Eli Lilly and Company, GlaxoSmithKline plc, and Johnson & Johnson Services, Inc. bring valuable clinical insights that help drive regulatory and market dynamics.

Innovative firms such as Merck & Co., Inc., Novartis AG, and Sanofi S.A. continue to push the boundaries of peptide application in diverse therapeutic areas, while specialized entities like Pepscan Therapeutics B.V., PeptiDream Inc., Pfizer Inc., SciTide LLC, and Zealand Pharma AS are at the forefront of next-generation peptide research. The collective efforts of these companies are instrumental in navigating the challenges and opportunities inherent in the cyclic peptides market, paving the way for a future defined by molecular precision and transformative healthcare solutions.

The report delves into recent significant developments in the Cyclic Peptides Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., AnaSpec, Astellas Inc., Asymchem Inc., Bachem Holding AG, Bristol-Myers Squibb Company, Clariant International Ltd, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Insamo, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pepscan Therapeutics B.V., PeptiDream Inc., Pfizer Inc., Sanofi S.A., SciTide LLC, and Zealand Pharma AS. Actionable Recommendations for Industry Leaders Driving Market Evolution

Industry leaders must adopt a strategic and data-driven approach to navigate the rapidly evolving cyclic peptides market. It is imperative to invest in advanced synthesis technologies and robust R&D programs that can streamline the discovery and production of new cyclic peptide formulations. By leveraging breakthroughs in liquid-phase and solid-phase synthesis, companies can accelerate development timelines and enhance product quality, ensuring a competitive edge in the global market.

Fostering strategic collaborations with academic institutions and specialized research centers is also recommended, as such partnerships can provide access to cutting-edge innovations and facilitate the translation of laboratory findings into viable commercial products. By closely monitoring segmentation trends-whether it be the evolving demands of diagnostic applications or the nuanced requirements of therapeutic interventions-organizations can align their product development strategies with market needs.

Furthermore, it is crucial to maintain agility in regulatory compliance and invest in comprehensive market research to identify emerging opportunities and potential challenges. Enhancing in-house capabilities while also exploring external strategic alliances will not only drive operational efficiency but will also bolster confidence among investors and stakeholders. In this way, industry leaders can create a resilient roadmap that capitalizes on innovation while mitigating risks in an increasingly competitive environment.

Conclusion: Embracing the Future of Cyclic Peptides

The evolution of the cyclic peptides market is a testament to the transformative potential of advanced biotechnology. With state-of-the-art synthesis technologies, a diversified segmentation strategy, and a robust network of global and regional stakeholders, this sector is poised for sustained growth and innovation. The synergies between academic excellence, corporate leadership, and regulatory foresight are creating a fertile ground for breakthrough discoveries that could redefine therapeutic paradigms.

It is evident that successful navigation of this complex market will require a keen understanding of both the scientific nuances and commercial imperatives that drive innovation. As we look to the future, the integration of multifaceted segmentation insights with strategic regional and corporate engagements will be key to unlocking the full potential of cyclic peptides. The ongoing advancements in technology and increasing cross-disciplinary collaboration underscore a promising horizon for next-generation therapeutics and diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases and cancer fuels demand for innovative cyclic peptides
      • 5.1.1.2. Expansion of biopharmaceutical industry with focus on peptide therapeutics enhances cyclic peptide demand
      • 5.1.1.3. Government incentives and grants for drug development encourage exploration of cyclic peptide therapeutics
    • 5.1.2. Restraints
      • 5.1.2.1. Issues with peptide stability and bioavailability
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovative applications of cyclic peptides in designing environmentally sustainable agrochemicals
      • 5.1.3.2. Innovative cyclic peptide modifications to improve pharmacokinetics in therapeutic development
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity in manufacturing of cyclic peptides
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing demand for natural cyclic peptide due to their ability to modulate biological pathways effectively
    • 5.2.2. Application: Rising application of cyclic peptides in diagnostics due to their high specificity and stability
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cyclic Peptides Market, by Type

  • 6.1. Introduction
  • 6.2. Natural Cyclic Peptide
  • 6.3. Synthetic Cyclic Peptide

7. Cyclic Peptides Market, by Product

  • 7.1. Introduction
  • 7.2. Antimicrobial Peptides
  • 7.3. Hormonal Peptides
    • 7.3.1. Insulin Analogs
    • 7.3.2. Peptide Hormone Therapy
  • 7.4. Immunomodulating Peptides
  • 7.5. Peptide Vaccines

8. Cyclic Peptides Market, by Technology

  • 8.1. Introduction
  • 8.2. Chemical Synthesis
  • 8.3. Hybrid Technology
  • 8.4. Liquid-Phase Synthesis
  • 8.5. Recombinant DNA Technology
  • 8.6. Solid-Phase Synthesis

9. Cyclic Peptides Market, by Application

  • 9.1. Introduction
  • 9.2. Diagnostics
    • 9.2.1. Biosensors
    • 9.2.2. Immunoassays
  • 9.3. Environmental Protection
  • 9.4. Research & Development
    • 9.4.1. Biochemical Analysis
    • 9.4.2. Drug Discovery
    • 9.4.3. Molecular Biology
  • 9.5. Therapeutics
    • 9.5.1. Cardiovascular
    • 9.5.2. Infectious Diseases
    • 9.5.3. Metabolic Disorders
    • 9.5.4. Oncology

10. Cyclic Peptides Market, by End User

  • 10.1. Introduction
  • 10.2. Academic Institutes
  • 10.3. Biotechnology Firms
  • 10.4. Pharmaceutical Companies

11. Americas Cyclic Peptides Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Cyclic Peptides Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Cyclic Peptides Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Leveraging generative AI to transform peptide macrocycle design
    • 14.3.2. Novartis strengthens its footprint in cyclic peptides and radiopharmaceuticals
    • 14.3.3. Exploring Roche's breakthrough in cyclic peptide KRAS inhibitors
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen Inc.
  • 2. AnaSpec
  • 3. Astellas Inc.
  • 4. Asymchem Inc.
  • 5. Bachem Holding AG
  • 6. Bristol-Myers Squibb Company
  • 7. Clariant International Ltd
  • 8. Eli Lilly and Company
  • 9. F. Hoffmann-La Roche AG
  • 10. GlaxoSmithKline plc
  • 11. Insamo
  • 12. Johnson & Johnson Services, Inc.
  • 13. Merck & Co., Inc.
  • 14. Novartis AG
  • 15. Pepscan Therapeutics B.V.
  • 16. PeptiDream Inc.
  • 17. Pfizer Inc.
  • 18. Sanofi S.A.
  • 19. SciTide LLC
  • 20. Zealand Pharma AS

LIST OF FIGURES

  • FIGURE 1. CYCLIC PEPTIDES MARKET MULTI-CURRENCY
  • FIGURE 2. CYCLIC PEPTIDES MARKET MULTI-LANGUAGE
  • FIGURE 3. CYCLIC PEPTIDES MARKET RESEARCH PROCESS
  • FIGURE 4. CYCLIC PEPTIDES MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL CYCLIC PEPTIDES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. CYCLIC PEPTIDES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. CYCLIC PEPTIDES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CYCLIC PEPTIDES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CYCLIC PEPTIDES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CYCLIC PEPTIDES MARKET DYNAMICS
  • TABLE 7. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY NATURAL CYCLIC PEPTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY SYNTHETIC CYCLIC PEPTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY INSULIN ANALOGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY PEPTIDE HORMONE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY IMMUNOMODULATING PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY CHEMICAL SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY HYBRID TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY LIQUID-PHASE SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY BIOSENSORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY ENVIRONMENTAL PROTECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY BIOCHEMICAL ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY MOLECULAR BIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. CHINA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 126. CHINA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 127. CHINA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 128. CHINA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 132. INDIA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 133. INDIA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. INDIA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 135. INDIA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 136. INDIA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 137. INDIA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 141. INDONESIA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. INDONESIA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. INDONESIA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 144. INDONESIA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 145. INDONESIA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 146. INDONESIA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 150. JAPAN CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 151. JAPAN CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. JAPAN CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 153. JAPAN CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 154. JAPAN CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 155. JAPAN CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 159. MALAYSIA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. MALAYSIA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. MALAYSIA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 162. MALAYSIA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 163. MALAYSIA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 164. MALAYSIA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 168. PHILIPPINES CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. PHILIPPINES CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 171. PHILIPPINES CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 172. PHILIPPINES CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 173. PHILIPPINES CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 177. SINGAPORE CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 178. SINGAPORE CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. SINGAPORE CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 180. SINGAPORE CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 181. SINGAPORE CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 182. SINGAPORE CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 186. SOUTH KOREA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 187. SOUTH KOREA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. SOUTH KOREA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 189. SOUTH KOREA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 190. SOUTH KOREA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 191. SOUTH KOREA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 195. TAIWAN CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 196. TAIWAN CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 197. TAIWAN CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 198. TAIWAN CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 199. TAIWAN CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 200. TAIWAN CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 204. THAILAND CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 205. THAILAND CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 206. THAILAND CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 207. THAILAND CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 208. THAILAND CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 209. THAILAND CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 213. VIETNAM CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 214. VIETNAM CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. VIETNAM CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 216. VIETNAM CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 217. VIETNAM CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 218. VIETNAM CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 232. DENMARK CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 233. DENMARK CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 234. DENMARK CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 235. DENMARK CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 236. DENMARK CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 237. DENMARK CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 241. EGYPT CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 242. EGYPT CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 243. EGYPT CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 244. EGYPT CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 245. EGYPT CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 246. EGYPT CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 250. FINLAND CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 251. FINLAND CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 252. FINLAND CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 253. FINLAND CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 254. FINLAND CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 255. FINLAND CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 259. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 260. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 261. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 262. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 263. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 264. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 268. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 269. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 270. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 271. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 272. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 273. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 277. ISRAEL CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 278. ISRAEL CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 279. ISRAEL CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 280. ISRAEL CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 281. ISRAEL CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 282. ISRAEL CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 283. ITALY CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 286. ITALY CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 287. ITALY CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 288. ITALY CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 289. ITALY CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 290. ITALY CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 291. ITALY CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 292. NETHERLANDS CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. NETHERLANDS CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 294. NETHERLANDS CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 295. NETHERLANDS CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 296. NETHERLANDS CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 297. NETHERLANDS CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 298. NETHERLANDS CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 299. NETHERLANDS CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 300. NETHERLANDS CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 301. NIGERIA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 302. NIGERIA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 303. NIGERIA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 304. NIGERIA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 305. NIGERIA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 306. NIGERIA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 307. NIGERIA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 308. NIGERIA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 309. NIGERIA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 310. NORWAY CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 311. NORWAY CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 312. NORWAY CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 313. NORWAY CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 314. NORWAY CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 315. NORWAY CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 316. NORWAY CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 317. NORWAY CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 318. NORWAY CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 319. POLAND CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. POLAND CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 321. POLAND CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 322. POLAND CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 323. POLAND CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 324. POLAND CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 325. POLAND CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 326. POLAND CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 327. POLAND CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 328. QATAR CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 329. QATAR CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 330. QATAR CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 331. QATAR CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 332. QATAR CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 333. QATAR CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 334. QATAR CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 335. QATAR CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 336. QATAR CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 337. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 338. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 339. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 340. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 341. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 342. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 343. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 344. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 345. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 346. SAUDI ARABIA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 347. SAUDI ARABIA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 348. SAUDI ARABIA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 349. SAUDI ARABIA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 350. SAUDI ARABIA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 351. SAUDI ARABIA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 352. SAUDI ARABIA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 353. SAUDI ARABIA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 354. SAUDI ARABIA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 355. SOUTH AFRICA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 356. SOUTH AFRICA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 357. SOUTH AFRICA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 358. SOUTH AFRICA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 359. SOUTH AFRICA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 360. SOUTH AFRICA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 361. SOUTH AFRICA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 362. SOUTH AFRICA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 363. SOUTH AFRICA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 364. SPAIN CYCLIC PEPTIDES MARKET SIZE, BY T